Overview

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

Status:
Terminated

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.

Phase:

Phase 3

Details

Lead Sponsor:

XOMA (US) LLC